Standard Biotools Inc.
LAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001162194
No open-market purchases or sales by Standard Biotools Inc. insiders were filed in the last 90 days; 143 institutions reported holding it in 13F filings for Q2 2026, worth $243.6M in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q1 2020
Institutional positions in Standard Biotools Inc. as of Mar 31, 2020. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1
- No complete 13F data for Q4 2019
- Shares held
- 1.85K
- No complete 13F data for Q4 2019
- Total value
- $4.71K
- No complete 13F data for Q4 2019
Holders and value by quarter
Institutions reporting LAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 143 | $243.6M |
| Q1 2026 | 156 | $273.4M |
| Q4 2025 | 159 | $387.4M |
| Q3 2025 | 155 | $371.7M |
| Q2 2025 | 160 | $337.1M |
| Q1 2025 | 145 | $307.8M |
| Q4 2024 | 142 | $487.1M |
| Q3 2024 | 141 | $542.9M |
| Q2 2024 | 145 | $480.4M |
| Q1 2024 | 145 | $761.9M |
| Q4 2023 | 86 | $116.4M |
| Q3 2023 | 72 | $137.5M |
| Q2 2023 | 66 | $89.1M |
| Q1 2023 | 69 | $89.9M |
| Q4 2022 | 68 | $54.4M |
| Q3 2022 | 65 | $42.5M |
| Q2 2022 | 86 | $70.2M |
| Q1 2022 | 109 | $179.6M |
| Q4 2021 | 121 | $221.2M |
| Q3 2021 | 119 | $386.6M |
| Q2 2021 | 113 | $354.4M |
| Q1 2021 | 138 | $268.7M |
Institutions, Q1 2020
Shares, value and share of portfolio for each institution holding Standard Biotools Inc..
Our 13F data for Q4 2019 is incomplete, so changes from the previous quarter aren't shown.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Advisors Asset Management, Inc. | 1,854 | $4.71K | 0.00% | – | – |